Stock listing
Helix Biopharma Corp.
Selected listing: HBP · NEO · CAD · CA
Helix Biopharma Corp. (Cboe Canada: HBP), Health Technology. Latest release Sep 28, 2026: Helix BioPharma Strengthens Biotech Leadership and Corporate…
- Ticker
- Cboe Canada: HBP
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- Cboe Canada
- Currency
- CAD
About Helix Biopharma Corp.
The company focuses on developing innovative therapies for cancer treatment. Helix Biopharma aims to advance its proprietary technology to improve patient outcomes in oncology.
Latest news from Helix Biopharma Corp.
Helix BioPharma Strengthens Biotech Leadership and Corporate Governance Through Planned Board Changes
September 28, 2026
Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development
August 17, 2026
Helix Biopharma Corp. Announces Board Composition Changes
August 14, 2026
Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development
June 30, 2026
Helix BioPharma : Q3 2026 MD&A | Management’s discussion and analysis of financial condition and results of operations
June 15, 2026
Research Helix Biopharma Corp.
Helix Biopharma Corp. company profile
View the public company page for Helix Biopharma Corp. on 6ix.
Helix Biopharma Corp. news
Read company news and market updates connected to Helix Biopharma Corp..
Helix Biopharma Corp. investor events
Find investor webinars, events, and replay context for Helix Biopharma Corp..
Alternate listings
HBP:TSX
CA · CAD
Alternate listing for Helix Biopharma Corp.; the primary context on this page is HBP:NEO.
HBPCF:OTC
US · USD
Alternate listing for Helix Biopharma Corp.; the primary context on this page is HBP:NEO.
HBP0:FWB
DE · EUR
Alternate listing for Helix Biopharma Corp.; the primary context on this page is HBP:NEO.